Home > Boards > US Listed > Medical - Equipment > Cardiovascular Systems Inc. (CSII)

The company’s second-quarter revenues increased 38 percent to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 409
Posts 55,045
Boards Moderated 15
Alias Born 12/16/01
160x600 placeholder
Cardiovascular Systems EPS misses by $0.04, beats on revenue Seeking Alpha - 5/6/2021 4:26:26 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2021 4:20:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 4:11:42 PM
Cardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial Results Business Wire - 5/6/2021 4:05:00 PM
Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Trea... Business Wire - 5/3/2021 4:05:00 PM
Cardiovascular Systems, Inc. to Participate at BofA Securities 2021 Health Care Conference Business Wire - 4/27/2021 7:00:00 AM
Cardiovascular Systems, Inc. to Webcast Fiscal 2021 Third-Quarter Earnings Conference Call Thursday, May 6 Business Wire - 4/15/2021 7:00:00 PM
Cardiovascular Systems enters investment and acquisition option agreement with Carepics Seeking Alpha - 4/8/2021 11:07:18 AM
Cardiovascular Systems, Inc. Announces Investment and Acquisition Option Agreement With Telehealth Company, CarePICS, LLC Business Wire - 4/8/2021 7:00:00 AM
Cardiovascular Systems, Inc. to Participate at the 20th Annual Needham Healthcare Conference Business Wire - 3/24/2021 7:00:00 AM
Cardiovascular Systems Buys WavePoint Medical’s Peripheral Support Catheters TipRanks - 3/23/2021 5:55:21 AM
Cardiovascular Systems acquires peripheral support catheters from WavePoint Medical Seeking Alpha - 3/22/2021 9:19:11 AM
Cardiovascular Systems, Inc. Announces Acquisition of Peripheral Support Catheters From WavePoint Medical, LLC Business Wire - 3/22/2021 9:00:00 AM
Cardiovascular Systems launches Wirion embolic protection device Seeking Alpha - 3/17/2021 12:32:26 PM
Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection System Business Wire - 3/17/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 2:41:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 1:25:18 PM
Cardiovascular Systems, Inc. to Participate at Four Upcoming Investor Conferences Business Wire - 2/11/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 10:43:58 AM
First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System Business Wire - 2/8/2021 4:05:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/4/2021 4:07:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/3/2021 4:09:07 PM
Cardiovascular Systems, Inc. Reports Fiscal 2021 Second-quarter Financial Results Business Wire - 2/3/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/1/2021 6:29:13 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 2/1/2021 6:28:15 PM
TREND1 Member Level  Thursday, 01/29/15 10:26:37 PM
Re: None
Post # of 63 
The company’s second-quarter revenues increased 38 percent to $44.7 million, from $32.3 million in the second quarter of fiscal 2014. Coronary revenues grew to $6.3 million. Customer reorder revenues remained strong at 95 percent of total revenue, compared to 96 percent a year ago. The gross profit margin increased to 79 percent from 77 percent, benefiting from higher average selling prices of coronary products and lower device unit costs than in the prior-year quarter.

CSI’s fiscal 2015 second-quarter net loss was $(5.3) million, or $(0.17) per common share, compared to a net loss of $(8.7) million, or $(0.32) per common share, in the fiscal 2014 second quarter. Adjusted EBITDA improved to $(1.3) million compared to $(4.6) million a year earlier. Losses narrowed from the prior year as revenue gains exceeded the growth of planned investments, including over $12 million related to the coronary market. Overall, expenses were favorable to guidance, due to lower than expected expenses for sales force expansion and timing of projects. Excluding net coronary investments, adjusted EBITDA was positive for the quarter.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences